Shattuck Labs (STTK) EBT (2019 - 2026)
Shattuck Labs (STTK) posted quarterly EBT of -$14.8 million for Q1 2026, down 7.78% year-over-year from -$16.0 million in Q1 2025, and up 87.7% quarter-over-quarter from -$120.1 million in Q4 2025.
Shattuck Labs (STTK) EBT (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported EBT for 8 consecutive years, with -$14.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 7.78% year-over-year to -$14.8 million; the TTM figure through Mar 2026 stood at -$159.1 million (up 7.49% YoY), while the FY2025 annual figure was -$155.5 million, up 9.08% from the prior year.
- EBT improved to -$14.8 million in Q1 2026 per STTK's latest filing, from -$120.1 million in the prior quarter.
- Across five years, EBT topped out at -$11.1 million in Q3 2025 and bottomed at -$120.1 million in Q4 2025.
- Historically, EBT has averaged -$38.3 million across 5 years, with a median of -$26.1 million in 2022.
- Annual changes were most pronounced in 2023 — EBT sank 265.61% — and 2025, when it surged 57.77%.
- Shattuck Labs' EBT stood at -$26.1 million in 2022, then tumbled by 265.61% to -$95.3 million in 2023, then dropped by 20.9% to -$115.3 million in 2024, then declined by 4.16% to -$120.1 million in 2025, then soared by 87.7% to -$14.8 million in 2026.
- Business Quant data shows STTK's EBT at -$14.8 million in Q1 2026, -$120.1 million in Q4 2025, and -$11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | -30.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.13 Mn |
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -120.06 Mn |
| Sep 30, 2025 | -11.12 Mn |
| Jun 30, 2025 | -13.13 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -115.26 Mn |
| Sep 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -24.26 Mn |
| Mar 31, 2024 | -32.44 Mn |
| Dec 31, 2023 | -95.34 Mn |
| Sep 30, 2023 | -28.70 Mn |
| Jun 30, 2023 | -23.05 Mn |
| Mar 31, 2023 | -21.86 Mn |
| Dec 31, 2022 | -26.08 Mn |
| Sep 30, 2022 | -31.67 Mn |
| Jun 30, 2022 | -29.15 Mn |
| Mar 31, 2022 | -31.11 Mn |
| Dec 31, 2021 | -22.41 Mn |
| Sep 30, 2021 | -36.63 Mn |